A retrospective comparative outcome analysis following systemic therapy in Mycosis Fungoides and Sezary Syndrome
Conclusions: With the exception of interferon, retinoids, or ECP, durable responses are rarely achieved with systemic therapies in MF/SS patients, particularly those with advanced‐stage disease. Therefore, clinical trial participation with novel agents should be encouraged. This article is protected by copyright. All rights reserved.
Source: American Journal of Hematology - Category: Hematology Authors: Walter Hanel, Robert Briski, Charles W. Ross, Thomas F. Anderson, Mark S. Kaminski, Alexandra C. Hristov, Ryan A Wilcox Tags: Research Article Source Type: research
More News: Chemotherapy | Clinical Trials | Cutaneous T cell lymphoma | Databases & Libraries | Hematology | Lymphoma | Mycosis Fungoides | Palliative | Palliative Care | Sezary Syndrome